Ⓒ 2024 Beye.com. All rights reserved.
This content is intended for health care professionals and providers only. The information contained on Beye.com, including text, graphics, images, and interactive activities, is for informational purposes only, and is not intended to be a substitute for professional medical advice. Beye LLC, via its Editors and Publisher, accepts no responsibility for any injury or damage to persons or property occasioned through the implementation of any ideas or use of any product described herein. Although great care is taken to ensure that all information is accurate, it is recommended that readers seek independent verification of advice on drugs and other product usage, surgical techniques and clinical processes prior to their use. References made in article may indicate usage of medical equipment or drugs at dosages, for periods of time, and in combination not included in the current prescribing information. Inclusion of advertising materials on the website thereof, does not constitute and representation or guarantee by Beye LLC of the quality of such products, or of the claims made.
→ Prescriptions per month
Annual revenue
$26,160
Pharmacy callbacks
0
Prescription prior authorizations
0
Annual Earnings
$5,232
Patient monthly expense
$50
Annual Revenue
$0
Staff time per month (hours)
44
Annual payroll expenses
$14,650
Annual earnings
-$14,650
Patient monthly expense
$513
Klarity C-Drops (Imprimis Pharmaceuticals), a compounded formulation in the Total Tears portfolio, is a 0.1% concentration of cyclosporine in a patented chondroitin sulfate/dextran/glycerol based vehicle with anti-inflammatory properties that protects and lubricates the cornea. Patients obtain the cyclosporine/chondroitin sulfate prescription as an out-of-pocket expense which eliminates the hassles of coupon eligibility concerns, time-consuming prior authorizations, and pharmacy callbacks. Klarity C-Drops can be shipped in bulk from Imprimis’ 503B facility and dispensed by practices or patients can fax a mail order form to Imprimis and receive the medications in a few days. Practices can obtain a discount when ordering bulk quantities to dispense directly to patients. Depending on dosing regimen, each bottle should last one month.
An estimated 4.88 million Americans over the age of 50 are affected by dry eye disease. [1] This tool was developed to assess the cost-benefits of prescribing branded and compounded dry eye medications. Sample values are already entered in the calculator fields, but you can adjust them to reflect your circumstances. This tool reflects the most common factors associated with prescribing practices and the average lowest price for commonly prescribed dry eye therapies according to GoodRx.com (accessed September 2018) but cannot account for every factor or variation.
1. https://www.aao.org/newsroom/eye-health-statistics